News

News

Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

10.03.2014

AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.

LinkedIn1Twitter1Facebook0Google+0tumblr

Comments are closed.

L’ANSM facilite la mise à disposition de chlorméthine (ou méchloréthamine) en gel pour le traitement du mycosis fongoïde
FDA approves Trulicity to treat type 2 diabetes
FDA approves Movantik for opioid-induced constipation
AEMPS: Información a los laboratorios titulares de medicamentos de uso humano que contienen Diacereína: Decisión de la Comisión C(2014) 6383 final, de fecha 4.9.2014
AEMPS: Agomelatina (Thymanax®, Valdoxan®) y toxicidad hepática: nuevas recomendaciones de uso
ANSM: Médicaments à base d’ambroxol ou de bromhexine, agomélatine (Valdoxan) – retour d’information sur le PRAC de septembre 2014
FDA approves weight-management drug Contrave
EMA: Meeting highlights from the PRAC 8-11 September 2014
EMA Regulatory information – Further guidance on adaptive licensing pilot project available
FDA Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations